

HB 2074 STAFF MEASURE SUMMARY

House Committee On Health Care

Action Date: 03/02/21

Action: Do pass and be referred to Ways and Means by prior reference

Vote: 10-0-0-0

Yeas: 10 - Alonso Leon, Campos, Dexter, Drazan, Hayden, Moore-Green, Noble, Prusak, Salinas, Schouten

Fiscal: Fiscal impact issued

Revenue: No revenue impact

Prepared By: Brian Nieubuurt, LPRO Analyst

Meeting Dates: 2/18, 3/2

WHAT THE MEASURE DOES:

Increases prescription drug monitoring program fees from \$25 to \$35 beginning January 1, 2022. Takes effect on 91st day following adjournment sine die.

ISSUES DISCUSSED:

- Oregon Prescription Drug Monitoring Program (PDMP); integration of PDMP into electronic workflow; new data elements
- Increase in use of the program among providers
- Oregon opioid epidemic
- Prior legislation modifying and expanding the scope of the PDMP (HB 2125 (2016); HB 3440 (2017); HB 4143 (2018); HB 2257 (2019))
- Yearly increase in the number of providers registered to use the PDMP; expanded revenue base

EFFECT OF AMENDMENT:

No amendment.

BACKGROUND:

The Oregon Prescription Drug Monitoring Program (PDMP) was established in 2009 to help healthcare providers and pharmacists provide patients better care in managing their prescriptions. Oregon-licensed retail pharmacies submit prescription data to the PDMP system for all Schedule II, III, and IV controlled substances dispensed to Oregon residents. Oregon-licensed healthcare providers, pharmacists, and their staff may be authorized to access information from the PDMP system to help determine which medications may be best for their patients. Fees for the PDMP have not been increased since the program's creation.

House Bill 2074 increases annual prescription monitoring program fees for individuals licensed by the Oregon Board of Pharmacy to prescribe controlled substances from \$25 to \$35.